GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Quest Diagnostics Inc (FRA:QDI) » Definitions » EV-to-EBITDA

Quest Diagnostics (FRA:QDI) EV-to-EBITDA : 11.59 (As of May. 08, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Quest Diagnostics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Quest Diagnostics's enterprise value is €18,660 Mil. Quest Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €1,611 Mil. Therefore, Quest Diagnostics's EV-to-EBITDA for today is 11.59.

The historical rank and industry rank for Quest Diagnostics's EV-to-EBITDA or its related term are showing as below:

FRA:QDI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.04   Med: 10.92   Max: 14.55
Current: 11.53

During the past 13 years, the highest EV-to-EBITDA of Quest Diagnostics was 14.55. The lowest was 6.04. And the median was 10.92.

FRA:QDI's EV-to-EBITDA is ranked better than
61.21% of 116 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.255 vs FRA:QDI: 11.53

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-08), Quest Diagnostics's stock price is €125.80. Quest Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €6.870. Therefore, Quest Diagnostics's PE Ratio for today is 18.31.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Quest Diagnostics EV-to-EBITDA Historical Data

The historical data trend for Quest Diagnostics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest Diagnostics EV-to-EBITDA Chart

Quest Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.70 8.14 7.79 12.02 11.71

Quest Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.39 12.57 11.57 11.71 11.35

Competitive Comparison of Quest Diagnostics's EV-to-EBITDA

For the Diagnostics & Research subindustry, Quest Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest Diagnostics's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Quest Diagnostics's EV-to-EBITDA falls into.



Quest Diagnostics EV-to-EBITDA Calculation

Quest Diagnostics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=18659.686/1610.535
=11.59

Quest Diagnostics's current Enterprise Value is €18,660 Mil.
Quest Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,611 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quest Diagnostics  (FRA:QDI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Quest Diagnostics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=125.80/6.870
=18.31

Quest Diagnostics's share price for today is €125.80.
Quest Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.870.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Quest Diagnostics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Quest Diagnostics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest Diagnostics (FRA:QDI) Business Description

Traded in Other Exchanges
Address
500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Quest Diagnostics (FRA:QDI) Headlines

No Headlines